Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · IEX Real-Time Price · USD
7.33
-0.23 (-3.04%)
At close: Jul 19, 2024, 4:00 PM
7.32
-0.01 (-0.14%)
Pre-market: Jul 20, 2024, 9:29 AM EDT

Acrivon Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Net Income
-64.12-60.39-31.17-16.24-5.31
Depreciation & Amortization
1.451.311.10.830.01
Share-Based Compensation
12.3211.622.190.50
Other Operating Activities
1.994.82-2.230.932.49
Operating Cash Flow
-48.37-42.64-30.12-13.98-2.8
Capital Expenditures
-2.08-1.29-2.17-0.24-0.02
Change in Investments
49.3252.01-139.5100
Investing Cash Flow
47.2450.72-141.68-0.24-0.02
Share Issuance / Repurchase
0.850.78104.4800
Debt Issued / Paid
00000.06
Other Financing Activities
-2.58-2.33-2.77112.222.83
Financing Cash Flow
-1.73-1.55101.71112.222.89
Net Cash Flow
-2.856.52-70.08980.07
Free Cash Flow
-50.45-43.93-32.28-14.22-2.82
Free Cash Flow Per Share
-2.23-1.99-7.83-8.16-1.97
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).